Historical Valuation
ENDRA Life Sciences Inc (NDRA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.33. The fair price of ENDRA Life Sciences Inc (NDRA) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：4.65
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
ENDRA Life Sciences Inc (NDRA) has a current Price-to-Book (P/B) ratio of 19.70. Compared to its 3-year average P/B ratio of 3.28 , the current P/B ratio is approximately 501.27% higher. Relative to its 5-year average P/B ratio of 3.48, the current P/B ratio is about 466.69% higher. ENDRA Life Sciences Inc (NDRA) has a Forward Free Cash Flow (FCF) yield of approximately -101.99%. Compared to its 3-year average FCF yield of -181.88%, the current FCF yield is approximately -43.92% lower. Relative to its 5-year average FCF yield of -126.54% , the current FCF yield is about -19.40% lower.
P/B
Median3y
3.28
Median5y
3.48
FCF Yield
Median3y
-181.88
Median5y
-126.54
Competitors Valuation Multiple
AI Analysis for NDRA
The average P/S ratio for NDRA competitors is 1436.13, providing a benchmark for relative valuation. ENDRA Life Sciences Inc Corp (NDRA.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for NDRA
1Y
3Y
5Y
Market capitalization of NDRA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of NDRA in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is NDRA currently overvalued or undervalued?
ENDRA Life Sciences Inc (NDRA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.33. The fair price of ENDRA Life Sciences Inc (NDRA) is between to according to relative valuation methord.
What is ENDRA Life Sciences Inc (NDRA) fair value?
NDRA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of ENDRA Life Sciences Inc (NDRA) is between to according to relative valuation methord.
How does NDRA's valuation metrics compare to the industry average?
The average P/S ratio for NDRA's competitors is 1436.13, providing a benchmark for relative valuation. ENDRA Life Sciences Inc Corp (NDRA) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for ENDRA Life Sciences Inc (NDRA) as of Jan 10 2026?
As of Jan 10 2026, ENDRA Life Sciences Inc (NDRA) has a P/B ratio of 19.70. This indicates that the market values NDRA at 19.70 times its book value.
What is the current FCF Yield for ENDRA Life Sciences Inc (NDRA) as of Jan 10 2026?
As of Jan 10 2026, ENDRA Life Sciences Inc (NDRA) has a FCF Yield of -101.99%. This means that for every dollar of ENDRA Life Sciences Inc’s market capitalization, the company generates -101.99 cents in free cash flow.
What is the current Forward P/E ratio for ENDRA Life Sciences Inc (NDRA) as of Jan 10 2026?
As of Jan 10 2026, ENDRA Life Sciences Inc (NDRA) has a Forward P/E ratio of -0.91. This means the market is willing to pay $-0.91 for every dollar of ENDRA Life Sciences Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for ENDRA Life Sciences Inc (NDRA) as of Jan 10 2026?
As of Jan 10 2026, ENDRA Life Sciences Inc (NDRA) has a Forward P/S ratio of 0.00. This means the market is valuing NDRA at $0.00 for every dollar of expected revenue over the next 12 months.